Analgesic Potentials of Preoperative Pregabalin,Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain

Model scores of the 29,894 trials active now.

Model score 6% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (741 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: combinationadjuvantintravenousstatusgiving
  Phrases that lowered it: kgthe effectthe pharmacokineticseffect ofsingle
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: 5.6% (lowers risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports marked serious: 62.3% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 5 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 88152 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 17516 (lowers risk) · Drug's FDA history
• Blinding: double (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Intra-operative Magnesium Sulphate for Post-operative Pain in Patients Undergoing Total Abdominal Hysterectomy Under General Anesthesia NCT06026527 · started 2024 · scored riskier than 14% of active trials completed
• Comparison of Postoperative Analgesic Effect of Intrathecal Magnesium and Fentanyl Added to Bupivacaine in Patients Undergoing Lower Limb Orthopedic Surgery NCT01205997 · started 2010 · scored riskier than 8% of active trials completed
• The Efface of Lidocaine vs. Magnesium Sulphate in the Management of Pain After Laparoscopic Cholecystectomy NCT07248332 · started 2024 · scored riskier than 9% of active trials completed
• Pregabalin in the Prevention of Postoperative Delirium and Pain NCT00819988 · started 2009 · scored riskier than 15% of active trials completed
• Perioperative Pregabalin for Reducing Opioid Consumption After Cardiac Surgery NCT04517110 · started 2021 · scored riskier than 27% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.